ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Merz Pharma and H. Lundbeck side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Merz PharmaH. Lundbeck
studies on the registry172276
open to participants now210
phase 3 studies under way57
reach primary completion within a year57
programswith a study of their own in two years16

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseMerz PharmaH. Lundbeck
Phase 100%

H. Lundbeck: 1 of its 6 programs at phase 1

  1. Lu AH69593phase 1
17%
Phase 200%

H. Lundbeck: 2 of its 6 programs at phase 2

  1. asedebartphase 2
  2. Lu AF28996phase 2
33%
Phase 300%

H. Lundbeck: 2 of its 6 programs at phase 3

  1. bexicaserinphase 3
  2. amlenetugphase 3
33%
Approved, new studies

Merz Pharma: 1 of its 1 programs at approved, new studies

  1. botulinum toxin type Aapproved, new study
100%

H. Lundbeck: 1 of its 6 programs at approved, new studies

  1. eptinezumabapproved, new study
17%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Merz Pharma1 readouts · 1 phase 3····

Merz Pharma, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. botulinum toxin type Aapproved, new study · Mar 0 · NCT07018700
·······
H. Lundbeck5 readouts · 2 phase 3·

H. Lundbeck, Dec ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. bexicaserinphase 3 · Dec 31 · NCT06660394
·

H. Lundbeck, Feb ’27: 1 program whose next study reaches primary completion

  1. Lu AH69593phase 1 · Feb 9 · NCT07613710

H. Lundbeck, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. eptinezumabapproved, new study · Mar 26 · NCT04965675
·

H. Lundbeck, May ’27: 1 program whose next study reaches primary completion

  1. Lu AF28996phase 2 · May 31 · NCT07513441
··

H. Lundbeck, Aug ’27: 1 program whose next study reaches primary completion

  1. asedebartphase 2 · Aug 10 · NCT06471829
··
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Merz Pharma

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

H. Lundbeck

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 2

Where they overlap

Conditions where at least two of them have programs: 1 in all. A program counts in each condition its studies name most.

ConditionMerz PharmaH. Lundbeck
Migraine Disordersboth · compare here

Merz Pharma in Migraine Disorders: 1 program

  1. botulinum toxin type Aapproved, new study

Their studies: Merz Pharma’s studies of Migraine Disorders in search

H. Lundbeck in Migraine Disorders: 1 program

  1. eptinezumabapproved, new study

Their studies: H. Lundbeck’s studies of Migraine Disorders in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Merz Pharma 1 of 1 · H. Lundbeck 1 of 6 programs (1 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.